Infusystem Hld SEC Filings

InfuSystem Holdings (INFU) reported higher Q3 results. Net revenues were $36,488k, up from $35,320k. Gross profit rose to $20,820k and operating income reached $3,811k. Net income was $2,259k, or $0.11 per diluted share, compared with $1,807k, or $0.08 per share, a year ago.

For the first nine months, net revenues were $107,206k versus $101,013k, with net income of $4,591k ($0.22 diluted). Cash provided by operating activities was $17,282k, reflecting stronger cash generation. The company repurchased $8,563k of common stock year-to-date under its $20,000k authorization.

Segment mix in Q3 showed Patient Services external revenue of $22,363k and Device Solutions external revenue of $14,125k. InfuSystem acquired certain assets of Apollo Medical Supply for $1,412k to expand wound care within Patient Services. The revolving credit facility had $21,360k outstanding and $53,640k available, with maturity extended to July 15, 2030.

InfuSystem Holdings (INFU) furnished its third-quarter 2025 results via an 8-K. The company reported that a press release detailing Q3 2025 financial results was provided under Item 2.02 and attached as Exhibit 99.1. The company states this information is furnished, not filed, under the Exchange Act, and therefore not subject to Section 18 liabilities. The filing also includes the Inline XBRL cover page file as Exhibit 104.

InfuSystem Holdings, Inc. announced it will disclose its third‑quarter 2025 financial results on November 4, 2025 before the market opens. The company will host a conference call for investors the same day at 9:00 a.m. Eastern Time.

The related press release is furnished as Exhibit 99.1.

InfuSystem Holdings (INFU) insider transaction: EVP-Chief HR Officer Jerod Funke reported RSU settlement on October 9, 2025. Restricted stock units converted into common stock on a one-for-one basis, resulting in 12,500 shares acquired at $0 per share via code “M”. To cover taxes, the issuer withheld 3,669 shares at $9.61 under code “F”.

After these transactions, Funke directly owned 18,662 shares of InfuSystem common stock.

Insider filing for Carrie Lachance, President and CEO of InfuSystem Holdings (INFU). On 09/23/2025, 50,000 performance-based restricted stock units granted May 16, 2025, vested and were settled into common stock. The issuer withheld 19,675 shares to cover tax withholding at an indicated value of $10.22 per share, leaving the reporting person with 232,174 shares beneficially owned after the transactions. The Form 4 shows the reporting person held 201,849 shares before the vesting, which increased to 251,849 upon settlement then decreased due to withholding. This filing documents routine equity compensation vesting and related tax withholding by an executive who is also a director.

InfuSystem Holdings insider Scott Shuda reported changes in beneficial ownership. Mr. Shuda, identified as a director, disclosed indirect ownership of 298,383 shares through entities Meridian and BlueLine. He recorded a distribution on 07/07/2025 that reduced holdings by 2,242 shares and a sale on 08/22/2025 of 5,752 shares at an average price of $9.67 (individual sale prices ranged $9.57–$9.83). Following the reported transactions, the filing shows 94,000 shares owned (direct or indirect) after the August sale. The Form 4 notes the sold shares originated from a dissolved partnership and no further sales are planned relating to that partnership.

InfuSystem Holdings, Inc. (INFU) filed a Form 144 notifying an intended open-market sale of 5,752 common shares through Charles Schwab with an aggregate market value of $56,455. The filing states the shares were originally acquired on 08/01/2017 via open-market purchase and payment in cash. The proposed approximate sale date is 08/22/2025, and the filing reports 20,425,964 shares outstanding for the issuer. No securities of the issuer were reported sold by the same person in the past three months. The filer affirms they are not aware of any undisclosed material adverse information.